---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117682"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:44:13.482666+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues

## Summary
- Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.
- Cash and cash equivalents $10.6M as of Sep 30, 2022, down from $13.0M at Dec 31, 2021.
- Phase 2b trial for C. difficile infection enrollment ongoing; added sites, expecting up to 30 total.
- Raised $4.225M in July 2022 via registered direct offering to institutional investor and executives.
- R&D expenses $1.6M in Q3 2022 vs $1.1M in Q3 2021, increase due to Phase 2b costs.

## SEC filing metadata
- accession: 0001104659-22-117682
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/tm2229909d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117682
- JSON: https://secwatch.observer/filing/0001104659-22-117682.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117682.txt

## Key facts
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $3.5 million, EPS $0.32 per diluted share.
  - Period: the quarter ended September 30, 2022
  - Net income: net loss of $3.5 million
  - EPS: $0.32 per diluted share
  - Result: reported results
  source text: The Company reported a net loss of $3.5 million or $0.32 per diluted share for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the nine months ended September 30, 2022 results: net income net loss of $8.8 million, EPS $0.84 per share.
  - Period: the nine months ended September 30, 2022
  - Net income: net loss of $8.8 million
  - EPS: $0.84 per share
  - Result: reported results
  source text: a net loss of $8.8 million or $0.84 per share for the nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.